HK1086186A1 - Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain - Google Patents

Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain

Info

Publication number: HK1086186A1
Authority: HK; Hong Kong
Prior art keywords: spongosine; treatment; pain; methoxyadenosein; preparing pharmaceutical
Prior art date: 2002-12-09

Application number

HK06106093.7A

Other languages

English (en)

Inventor

Peter Richardson

Original Assignee

Cambridge Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-09

Filing date

2006-05-26

Publication date

2006-09-15

2006-05-26 Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd

2006-09-15 Publication of HK1086186A1 publication Critical patent/HK1086186A1/xx

Links

AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 title abstract 5
AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 title abstract 5
150000003838 adenosines Chemical class 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Mechanical Treatment Of Semiconductor (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HK06106093.7A 2002-12-09 2006-05-26 Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain HK1086186A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0228723.3A GB0228723D0 (en)	2002-12-09	2002-12-09	Treatment of pain
PCT/GB2003/005379 WO2004052377A1 (en)	2002-12-09	2003-12-09	Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia

Publications (1)

Publication Number	Publication Date
HK1086186A1 true HK1086186A1 (en)	2006-09-15

Family

ID=9949371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK06106093.7A HK1086186A1 (en)	2002-12-09	2006-05-26	Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain

Country Status (19)

Country	Link
US (2)	US8252766B2 (xx)
EP (1)	EP1581235B1 (xx)
JP (2)	JP4836454B2 (xx)
KR (1)	KR101122495B1 (xx)
CN (2)	CN100471503C (xx)
AT (1)	ATE430572T1 (xx)
AU (1)	AU2003288451B2 (xx)
CA (1)	CA2507918A1 (xx)
CY (1)	CY1109229T1 (xx)
DE (1)	DE60327557D1 (xx)
DK (1)	DK1581235T3 (xx)
ES (1)	ES2326532T3 (xx)
GB (2)	GB0228723D0 (xx)
HK (1)	HK1086186A1 (xx)
NO (1)	NO20053042L (xx)
NZ (1)	NZ540353A (xx)
PT (1)	PT1581235E (xx)
SI (1)	SI1581235T1 (xx)
WO (1)	WO2004052377A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0228723D0 (en)	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB0305149D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Compounds for the treatment of pain
WO2005084653A2 (en) *	2004-03-05	2005-09-15	Cambridge Biotechnology Limited	Adenosine receptor agonists
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US8603779B2 (en)	2004-12-01	2013-12-10	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
GB0426394D0 (en) *	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
US8778634B2 (en)	2004-12-01	2014-07-15	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8399400B2 (en)	2004-12-01	2013-03-19	Syntaxin, Ltd.	Fusion proteins
US8512984B2 (en)	2004-12-01	2013-08-20	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0610867D0 (en) *	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain
EP2081932A2 (en)	2006-06-27	2009-07-29	BIOVITRUM AB (publ)	2-o'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor
CN101479289A (zh)	2006-06-27	2009-07-08	比奥维特罗姆上市公司	治疗化合物
ATE500263T1 (de)	2006-06-27	2011-03-15	Cbt Dev Ltd	Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
BRPI0907248A2 (pt) *	2008-01-09	2019-02-26	Pgxhealth, Llc	tratamento intratecal de dor neuropática com agonistas a2ar
US8221791B1 (en)	2008-12-10	2012-07-17	University Of Central Florida Research Foundation, Inc.	Silica-based antibacterial and antifungal nanoformulation
SG177557A1 (en) *	2009-07-09	2012-02-28	Cbt Dev Ltd	Combined preparation for use as a medicament
US20130123208A1 (en) *	2010-05-12	2013-05-16	The Regents of the University of Colorado, a body corporation	Method of treating multiple sclerosis with adenosine receptor agonists
EP2631345B1 (en) *	2012-02-27	2019-09-04	Electrolux Home Products Corporation N.V.	Washing tub unit and washing machine
US20140056870A1 (en)	2012-08-27	2014-02-27	Allergan, Inc.	Fusion proteins
EP3782636B1 (en) *	2016-02-04	2024-05-15	The Johns Hopkins University	Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792155A (fr)	1971-12-01	1973-05-30	Takeda Chemical Industries Ltd	Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (xx)	1971-12-01	1973-08-28
JPS5549594B2 (xx)	1972-12-08	1980-12-12
DE2359536C2 (de)	1972-12-08	1984-08-02	Takeda Chemical Industries, Ltd., Osaka	2,6-Diaminonebularinderivate
JPS5461194A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en)	1984-06-19	1987-11-10	Warner-Lambert Company	Adenosine receptor assay and kit
US5104859A (en) *	1985-09-24	1992-04-14	Solimedco Aktiebolag	Continuous administration of adenosine to reduce pulmonary vascular resistance
US5231086A (en) *	1985-09-24	1993-07-27	Item Development Aktiebolag	Continuous administration adenosine to increase myocardial blood flow
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en)	1990-02-20	1992-08-18	Whitby Research, Inc.	2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5677290A (en) *	1990-05-10	1997-10-14	Fukunaga; Atsuo F.	Therapeutic use of adenosine compounds as surgical anesthetics
US6004945A (en) *	1990-05-10	1999-12-21	Fukunaga; Atsuo F.	Use of adenosine compounds to relieve pain
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US6180616B1 (en) *	1990-05-10	2001-01-30	Atsuo F. Fukunaga	Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
AU6516494A (en)	1993-04-15	1994-11-08	New York University	Adenosine receptor agonists for the promotion of wound healing
US5683989A (en) *	1993-12-17	1997-11-04	Novo Nordisk A/S	Treatment of ischemias by administration of 2,N6 -substituted adenosines
SE9401499D0 (sv)	1994-05-02	1994-05-02	Item Dev Ab	New method of treatment
PL316985A1 (en)	1994-05-10	1997-03-03	Sandoz Ltd	Derivatives of adenosine
US5596094A (en)	1994-05-26	1997-01-21	Sandoz Ltd.	Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en)	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it)	1995-06-02	1997-08-05	Schering Plough S P A	Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
AU7449598A (en)	1997-05-23	1998-12-11	Nippon Shinyaku Co. Ltd.	Medicinal composition for prevention or treatment of hepatopathy
US6110902A (en)	1997-06-23	2000-08-29	Moehler; Hanns	Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CA2296485A1 (en)	1997-07-29	1999-02-11	Medco Research, Inc.	N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6440455B1 (en)	1997-09-02	2002-08-27	Children's Medical Center Corporation	Methods for modulating the axonal outgrowth of central nervous system neurons
GB9723590D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
JP2002500188A (ja)	1998-01-08	2002-01-08	ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション	Ａ２ａアデノシンレセプター作動因子
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
GB0228723D0 (en)	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB2412067B (en)	2002-12-23	2007-11-14	Global Cardiac Solutions Pty L	Organ preconditioning, arrest, protection, preservation and recovery (2)
GB0305150D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Use of therapeutic compounds
GB0305149D0 (en)	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Compounds for the treatment of pain
GB0305153D0 (en)	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Identification of therapeutic compounds
WO2005084653A2 (en)	2004-03-05	2005-09-15	Cambridge Biotechnology Limited	Adenosine receptor agonists
US8407664B2 (en)	2005-12-30	2013-03-26	Sap Ag	Software model business objects

2002
- 2002-12-09 GB GBGB0228723.3A patent/GB0228723D0/en not_active Ceased
2003
- 2003-12-09 EP EP03780370A patent/EP1581235B1/en not_active Expired - Lifetime
- 2003-12-09 PT PT03780370T patent/PT1581235E/pt unknown
- 2003-12-09 GB GB0328548A patent/GB2396108B/en not_active Expired - Fee Related
- 2003-12-09 NZ NZ540353A patent/NZ540353A/en not_active IP Right Cessation
- 2003-12-09 WO PCT/GB2003/005379 patent/WO2004052377A1/en active Application Filing
- 2003-12-09 DE DE60327557T patent/DE60327557D1/de not_active Expired - Lifetime
- 2003-12-09 CN CNB2003801055073A patent/CN100471503C/zh not_active Expired - Fee Related
- 2003-12-09 CN CN2008100922507A patent/CN101264097B/zh not_active Expired - Fee Related
- 2003-12-09 KR KR1020057010441A patent/KR101122495B1/ko not_active IP Right Cessation
- 2003-12-09 SI SI200331633T patent/SI1581235T1/sl unknown
- 2003-12-09 CA CA002507918A patent/CA2507918A1/en not_active Abandoned
- 2003-12-09 AU AU2003288451A patent/AU2003288451B2/en not_active Ceased
- 2003-12-09 US US10/537,564 patent/US8252766B2/en not_active Expired - Fee Related
- 2003-12-09 ES ES03780370T patent/ES2326532T3/es not_active Expired - Lifetime
- 2003-12-09 DK DK03780370T patent/DK1581235T3/da active
- 2003-12-09 AT AT03780370T patent/ATE430572T1/de active
- 2003-12-09 JP JP2004558826A patent/JP4836454B2/ja not_active Expired - Fee Related
2005
- 2005-06-21 NO NO20053042A patent/NO20053042L/no not_active Application Discontinuation
2006
- 2006-05-26 HK HK06106093.7A patent/HK1086186A1/xx not_active IP Right Cessation
2009
- 2009-07-14 CY CY20091100733T patent/CY1109229T1/el unknown
2010
- 2010-08-20 US US12/859,932 patent/US20110184065A1/en not_active Abandoned
- 2010-12-03 JP JP2010270287A patent/JP2011132229A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
GB2396108B (en)	2005-08-03
ATE430572T1 (de)	2009-05-15
US8252766B2 (en)	2012-08-28
EP1581235A1 (en)	2005-10-05
CN101264097A (zh)	2008-09-17
CA2507918A1 (en)	2004-06-24
US20070010475A1 (en)	2007-01-11
CN100471503C (zh)	2009-03-25
GB2396108A (en)	2004-06-16
NO20053042L (no)	2005-06-21
SI1581235T1 (sl)	2009-10-31
CY1109229T1 (el)	2013-09-04
GB0328548D0 (en)	2004-01-14
US20110184065A1 (en)	2011-07-28
ES2326532T3 (es)	2009-10-14
DE60327557D1 (de)	2009-06-18
CN1723026A (zh)	2006-01-18
AU2003288451B2 (en)	2009-06-04
WO2004052377A1 (en)	2004-06-24
GB0228723D0 (en)	2003-01-15
KR20050089815A (ko)	2005-09-08
JP4836454B2 (ja)	2011-12-14
JP2006514638A (ja)	2006-05-11
EP1581235B1 (en)	2009-05-06
NZ540353A (en)	2006-11-30
AU2003288451A1 (en)	2004-06-30
CN101264097B (zh)	2011-10-05
DK1581235T3 (da)	2009-08-31
PT1581235E (pt)	2009-07-07
KR101122495B1 (ko)	2012-03-15
JP2011132229A (ja)	2011-07-07

Legal Events

Date	Code	Title	Description
2014-07-04	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20131209

Publication	Publication Date	Title
HK1086186A1 (en)	2006-09-15	Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
HK1087629A1 (en)	2006-10-20	Compounds for the treatment of pain
NZ515567A (en)	2004-03-26	Method for treating chronic pain using MEK inhibitors
EG25822A (en)	2012-08-23	Quinolinyl-pyrrolopyrazoles
ECSP034922A (es)	2004-04-28	Pirrolopirimidinas
MY138059A (en)	2009-04-30	Use of ikb-kinase inhibitors in pain therapy
WO2004006842A3 (en)	2004-05-27	Combinations of drugs for the treatment of neoplasms
WO2003082260A3 (en)	2004-03-25	Tuberculosis treatment using pleuromutilin derivatives
SI1572167T1 (sl)	2008-12-31	Transdermalni buprenorfinski dozirni reĹľim za analgezijo
WO1992019617A3 (en)	1992-12-10	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
UA83821C2 (ru)	2008-08-26	Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
WO2004007676A3 (en)	2004-04-08	Combination therapy for the treatment of neoplasms
GB0020504D0 (en)	2000-10-11	Therapeutic method
TW200503666A (en)	2005-02-01	Treatment of type 1 diabetes with pde5 inhibitors
GEP201606538B (en)	2016-09-12	Preoperative treatment of post operative pain
WO2002076393A3 (en)	2003-04-03	Antiagionecic, antitumor, chemopreventative agents
WO2008060381A3 (en)	2008-11-27	Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
TW200501958A (en)	2005-01-16	A therapeutic agent for treating a behavioral disorder
EP1347754A4 (en)	2004-10-13	COMPOSITIONS FOR PREVENTION OF ADHESION
EP1011672A4 (en)	2001-04-04	CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM
PL367628A1 (en)	2005-03-07	Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
AU2003240842A1 (en)	2003-12-02	Synergistic combination of an opioid analgesic and a nsaid
WO2003032895A3 (en)	2005-12-08	Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
IL164092A0 (en)	2005-12-18	The use of devazepide as analgesic agent
GB0223379D0 (en)	2002-11-13	Combination therapy